Finance

Lists
TCRX:NASDAQ
Tscan Therapeutics Inc
၀.၃၁ US$
-၀.၁၆%
(-၀.၀၀၀၅၀) 1D
အောက် ၁, GMT-၄ ၁၂:၅၁:၂၉  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TCRX...
Open
၀.၃၂ US$
High
၀.၃၂ US$
Low
၀.၃၁ US$
Mkt. cap
၂.၁၆ ကုဋေ
Avg. vol.
၁.၀၂ သန်း
Volume
၃.၀၈ သိန်း
52-wk high
၂.၅၇ US$
52-wk low
၀.၂၉ US$
EPS
-၀.၉၁ US$
Beta
၁.၀၇
Shares outstanding
၆.၃၅ ကုဋေ
No. of employees
၁၃၈
Open
၀.၃၂ US$
High
၀.၃၂ US$
Low
၀.၃၁ US$
Mkt. cap
၂.၁၆ ကုဋေ
Avg. vol.
၁.၀၂ သန်း
Volume
၃.၀၈ သိန်း
52-wk high
၂.၅၇ US$
52-wk low
၀.၂၉ US$
EPS
-၀.၉၁ US$
Beta
၁.၀၇
Shares outstanding
၆.၃၅ ကုဋေ
No. of employees
၁၃၈
News stories
From web sources and news partners
TipRanks
TipRanks
·
ပြီးခဲ့သည့် ၁၉ နာရီ
TScan Therapeutics Announces Executive Departures Amid Reorganization
Stock Titan
Stock Titan
·
ပြီးခဲ့သည့် ၁၉ နာရီ
CFO and medical chief will leave by November 1, 2026, at TScan Therapeutics (TCRX).
About Tscan Therapeutics Inc
CEO-
Employees၁၃၈
Founded၂၀၁၈
HeadquartersWaltham, မက်ဆာချူးဆက်ပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websitetscan.com
Analyst ratings
Based on 6 analysts giving stock ratings to TCRX in the past 3 months
Hold
Buy
1
Hold
5
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for TCRX in the last 3 months.
Highest
Current ၀.၃၁ US$
၁.၀၀ US$ (+၂၁၈.၄၇%)
Average
၁.၀၀ US$ (+၂၁၈.၄၇%)
Lowest
၁.၀၀ US$ (+၂၁၈.၄၇%)
Analyst
Recommendation
Action
Price target
Projected
Date
Andres Y. Maldonado
H.C. Wainwright
Hold
Downgraded
၁.၀၀ US$
+၂၁၈.၅%
09/09/2026
Sam Slutsky
LifeSci Capital
Hold
Downgraded
-
-
09/02/2026
Gil Blum
Needham
Hold
Downgraded
-
-
09/02/2026
David Nierengarten
Wedbush
Hold
Downgraded
၁.၀၀ US$
+၂၁၈.၅%
09/03/2026
Maxwell Skor
Morgan Stanley
Hold
Maintained
-
-
08/17/2026
Tara Bancroft
TD Cowen
Buy
Maintained
-
-
08/12/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
၂.၅၁ သန်း
၂.၅၇ သန်း
၉.၈၂ သိန်း
၁.၀၅ သန်း
Cost of goods sold
၃.၁၇ ကုဋေ
၁.၈၄ ကုဋေ
၂.၁၉ ကုဋေ
၂.၃၄ ကုဋေ
Cost of revenue
၃.၁၇ ကုဋေ
၁.၈၄ ကုဋေ
၂.၁၉ ကုဋေ
၂.၃၄ ကုဋေ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၇.၈၇ သန်း
၅.၉၉ သန်း
၈.၂၂ သန်း
၈.၁၄ သန်း
Operating expense
၇.၈၇ သန်း
၅.၉၉ သန်း
၈.၂၂ သန်း
၈.၁၄ သန်း
Total operating expenses
၃.၉၆ ကုဋေ
၂.၄၄ ကုဋေ
၃.၀၁ ကုဋေ
၃.၁၅ ကုဋေ
Operating income
-၃.၇၁ ကုဋေ
-၂.၁၉ ကုဋေ
-၂.၉၁ ကုဋေ
-၃.၀၅ ကုဋေ
Other non operating income
-
-
-
-
EBT including unusual items
-၃.၅၇ ကုဋေ
-၂.၃၀ ကုဋေ
-၂.၈၇ ကုဋေ
-၃.၀၄ ကုဋေ
EBT excluding unusual items
-၃.၅၇ ကုဋေ
-၂.၁၀ ကုဋေ
-၂.၈၇ ကုဋေ
-၃.၀၄ ကုဋေ
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-၃.၅၇ ကုဋေ
-၂.၃၀ ကုဋေ
-၂.၈၇ ကုဋေ
-၃.၀၄ ကုဋေ
Net profit margin
-၁,၄၂၂.၁၄%
-၈၉၅.၀၉%
-၂,၉၁၉.၁၄%
-၂,၈၈၈.၅၈%
Earnings per share
-၀.၂၈
-၀.၁၈
-၀.၂၂
-၀.၂၃
Interest and investment income
၂.၀၄ သန်း
၁.၅၈ သန်း
၁.၁၆ သန်း
၈.၃၃ သိန်း
Interest expense
-၆.၉၉ သိန်း
-၇.၀၂ သိန်း
-၆.၈၉ သိန်း
-၆.၉၉ သိန်း
Net interest expenses
၁.၃၄ သန်း
၈.၈၁ သိန်း
၄.၇၃ သိန်း
၁.၃၄ သိန်း
Depreciation and amortization charges
-
-
-
-
EBITDA
-၃.၆၃ ကုဋေ
-၂.၁၁ ကုဋေ
-၂.၈၄ ကုဋေ
-၂.၉၈ ကုဋေ
Gain or loss from assets sale
-
-
-
၉.၉၀ သောင်း
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google အက်ပ်များ